Tahir Amin discusses his new book on how to change the pharmaceutical industry for the better.

If there is 1 book that you would like all global health students to read, it would be.....? Here is an impressive list of over 500 books

Podcast Episode · Public Health On Call · September 3 · 18m

A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen

Full Committee Hearing on July 14, 2026 at 6:15 AM

The tables have turned for the U.S. biosimilars market.  | With more than a decade since the first FDA biosim approval, strong launches of biologic copies of AbbVie’s Humira, J&J’s Stelara and Regener...

Please fill out this form to register for the event on June 11, 2026 at 6:00pm at The People's Forum.

Pharmaceutical monopolies, patent law, and global health access shaping drug pricing, power, and inequities in the U.S. and worldwide.

“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”

“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”

“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”

A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus.

A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus.

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

Please fill out this form to register for the event on June 11, 2026 at 6:00pm at The People's Forum.

Explore the ongoing struggle for affordable medicine access amidst global pharmaceutical monopolies and the need for systemic change.